A true endocrine disorder can slow weight reduction, alter appetite, increase fluid retention, and worsen body composition, but the phrase hormonal imbalance is too vague to explain a plateau by itself.
Insulin resistance can increase hunger, liver fat, glucose variability, and cardiometabolic risk while fasting glucose remains normal. It can make weight control harder, but it does not make a calorie deficit physiologically impossible.
Common variants near FTO can increase obesity susceptibility, often through appetite and satiety pathways, but they are not a genetic sentence and do not explain an individual’s entire weight history.
You cannot erase inherited sequence through willpower, but you can change the pathway from genetic susceptibility to obesity through environmental design, appetite treatment, exercise, medication, and surgery.
Parents transmit genes, appetite traits, household environments, early-life exposures, cultural routines, and socioeconomic constraints. Childhood obesity is inherited through a system, not one route.
Every patient deserves endocrine clinical assessment, but not every patient needs an indiscriminate hormone panel before obesity treatment begins.
Normal fasting glucose or HbA1c can coexist with hyperinsulinemia, visceral adiposity, fatty liver, hypertension, dyslipidemia, sleep apnea, and rising cardiovascular risk.
There is no universal hidden panel for obesity. The valuable tests are those that detect complications, identify selected secondary causes, establish treatment safety, or change the level of intervention.
Two people can eat apparently identical foods and show different weight trajectories because total exposure, absorption, body size, spontaneous activity, appetite compensation, sleep, genetics, microbiome, and measurement error differ.
Semaglutide is neither a miracle nor a cosmetic trick. At obesity-treatment doses it can produce clinically important weight loss and health benefits, but maintenance commonly requires continued treatment or another durable strategy.